New Supercritical Extraction Facility

Sabinsa Corporation, announced the completion of its new supercritical carbon dioxide extraction facility at Bangalore, India based SAMI Labs, the company's manufacturing division. According to Dr. Majeed, "this facility will provide additional opportunities for us to serve our customers better." The capacity of the plant is about 2000 kg feed material per day. Supercritical extraction is a two step process which uses a dense gas, carbon dioxide (CO_2), as a solvent above its critical temperature (31°C) and critical pressure (74 Bar).

As the extraction takes place at low temperatures in an inert solvent, the color, flavor and biological value of temperature sensitive materials remain unaffected.

Pulverized raw material is loaded into the extractor. Supercritical CO_2 is fed to the extractor through a high pressure pump and functions as a solvent The extract-laden CO_2 is then sent to a reduced pressure separator, where the extract separates.

A major advantage of supercritical extraction technology is that residual solvents are eliminated from the final product. This is of particular importance for botanical extracts and solvent based products. Of equal importance is the absence of heavy metals, since they are not extractable using this method even if they are present in the starting material. Supercritical extraction also significantly reduces the bio-burden, or microbial load, due to the pressurized use of carbon dioxide.

ForsLean®

Now Water Soluble

.Sabinsa Corporation announces availability of a new form of its award winning lean body mass promoting ingredient ForsLean® Water Soluble (WS), which greatly expands dosage form delivery options.

OUR INNOVATION IS YOUR ANSWER®

info@sabinsa.com

Visit Sabinsa's Websites

www.sabinsa.com
www.aquasolextracts.com
www.bacopin.com
www.bioperine.com
www.boswellin.com
www.curcuminc3complex.com
www.forslean.com
www.gugulipid.com
www.garcitrin.com
www.lactospore.com
www.saberry.net
www.seleniumselect.com
www.silbinol.com
www.tetrahydrocurcuminoids.com
www.venocin.com

ForsLean® is a proprietary ingredient that has been patented for its use in promoting lean body mass. Coleus forskohlii's weight management properties are not a traditional usage of the herb from which it is derived, and were discovered by Sabinsa. Sabinsa was granted US Patent # 5,804,596 for its use and composition in promotion of lean body mass, reduction of adipose tissue (fat) and weight loss. The dietary supplements containing ForsLean® WS will have it listed by name on the label.

ForsLean® is a registered trademark of the Sabinsa Corporation According to Mark C. Sysler, Sr. Executive V.P. Marketing & Sales, the material is generating increasing interest in manufacturing circles. The Hollywood Celebrity Diet group has come out with "Slender Water" using Sabinsa's Forslean® WS and Citrin® K. Slender Water was also handed out at the Cannes Film Festival in France, this May.

ForsLean® shifts the proportion between lean body mass and adipose or fatty tissue in favor of lean body mass, thereby improving general health. The effect can be measured by decreases in the waist hip ratio and the body mass index.

For more information please check the the ForsLean® websites:

Contact
Sabinsa
New Jersey office
(1-732-777-1111)

Utah office
(1-801-465-8400).

Sabinsa Corporation: In tune with the Biotech Century

Sabinsa Corporation entered the biotechnological age with the inception of a production facility at Nelamangala, near Bangalore. The first biotechnology/fermentation products to be manufactured at this facility were probiotics. Several new products are in the research pipeline at the Biotech R&D facility at Nelamangala.

These facilities are geared toward quality biotechnological products that find diverse applications in the nutritional, pharmaceutical, food and chemical industries.

Sabinsa develops new patent-pending process for African sleeping sickness drug

Dr. N. Kalyanam., President R & D along with his research group at Sabinsa's Princeton R & D lab, developed a simplified cost effective and affordable manufacturing process for eflornithine, a drug used to fight African sleeping sickness.

Sabinsa Corporation is working in collaboration with the WHO on this project, contributing to the organization's efforts to combat the parasitic disease

that has resurged in epidemic proportions in certain parts of Africa.

A patent application for this process was recently submitted to the United States Patent and Trademark Office.

Gugulipid® : Patent issued for Chemopreventive and Anti-inflammatory roles

US Patent 6,436,991 dated August 20, 2002, granted to Sabinsa Corporation, covers the antioxidant and cancer chemopreventive roles of constituents of Gugulipid®, the Commiphora mukul extract composition from Sabinsa Corporation.

This invention, titled "Compositions for prevention and treatment of abnormal cell growth and proliferation in inflammation, neoplasia and cardiovascular disease", further unravels the multifaceted healthful benefits of this increasingly popular phytonutrient.

PEOPLE FOCUS

Janet

Janet Thide is part of the Customer Service group at Sabinsa Corporation, Piscataway, NJ.

A native Texan, Janet earned her Bachelor of Business Administration in Marketing, from Lamar University in Texas. Janet's background is in the Financial Printing industry, Customer Service and Billing.

Ashmed Barrie

Ashmed Barrie Accounts Receivable Manager was recently promoted to Director of Logistics at Sabinsa Corporation. His responsibilities include overseeing the daily activity of the New Jersey shipping and receiving departments and personnel, along with warehouse and inventory management. Ashmed's years of background and experience in accounting and inventory management, would help him coordinate and further develop the systems already in place, in his areas of responsibility.